| hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer C Camps, FM Buffa, S Colella, J Moore, C Sotiriou, H Sheldon, AL Harris, ... Clinical cancer research 14 (5), 1340-1348, 2008 | 800 | 2008 |
| New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes H Sheldon, E Heikamp, H Turley, R Dragovic, P Thomas, CE Oon, R Leek, ... Blood, The Journal of the American Society of Hematology 116 (13), 2385-2394, 2010 | 475 | 2010 |
| microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer FM Buffa, C Camps, L Winchester, CE Snell, HE Gee, H Sheldon, ... Cancer research 71 (17), 5635-5645, 2011 | 380 | 2011 |
| The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis HE Gee, FM Buffa, C Camps, A Ramachandran, R Leek, M Taylor, M Patil, ... British journal of cancer 104 (7), 1168-1177, 2011 | 360 | 2011 |
| Recurrent PTPRB and PLCG1 mutations in angiosarcoma S Behjati, PS Tarpey, H Sheldon, I Martincorena, P Van Loo, G Gundem, ... Nature genetics 46 (4), 376-379, 2014 | 319 | 2014 |
| DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo JL Li, RCA Sainson, CE Oon, H Turley, R Leek, H Sheldon, E Bridges, ... Cancer research 71 (18), 6073-6083, 2011 | 270 | 2011 |
| MicroRNA-10b and breast cancer metastasis HE Gee, C Camps, FM Buffa, S Colella, H Sheldon, JM Gleadle, ... Nature 455 (7216), E8-E9, 2008 | 176 | 2008 |
| Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors H Sheldon, M Andre, JA Legg, P Heal, JM Herbert, R Sainson, ... The FASEB Journal 23 (2), 513, 2009 | 145 | 2009 |
| Identification and angiogenic role of the novel tumor endothelial marker CLEC14A M Mura, RK Swain, X Zhuang, H Vorschmitt, G Reynolds, S Durant, ... Oncogene 31 (3), 293-305, 2012 | 134 | 2012 |
| Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer M Morotti, E Bridges, A Valli, H Choudhry, H Sheldon, S Wigfield, N Gray, ... Proceedings of the National Academy of Sciences 116 (25), 12452-12461, 2019 | 124 | 2019 |
| Glutamine deprivation alters the origin and function of cancer cell exosomes SJ Fan, B Kroeger, PP Marie, EM Bridges, JD Mason, K McCormick, ... The EMBO Journal 39 (16), e103009, 2020 | 93 | 2020 |
| Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation SN Dos Santos, H Sheldon, JX Pereira, C Paluch, EM Bridges, ... Oncotarget 8 (30), 49484, 2017 | 85 | 2017 |
| Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4 U Harjes, E Bridges, KM Gharpure, I Roxanis, H Sheldon, F Miranda, ... Oncogene 36 (7), 912-921, 2017 | 73 | 2017 |
| Intracellular movement of green fluorescent protein–tagged phosphatidylinositol 3-kinase in response to growth factor receptor signaling H Gillham, MCHM Golding, R Pepperkok, WJ Gullick The Journal of cell biology 146 (4), 869-880, 1999 | 73 | 1999 |
| A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis G Kerr, H Sheldon, A Chaikuad, I Alfano, F von Delft, AN Bullock, ... Angiogenesis 18, 209-217, 2015 | 66 | 2015 |
| Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab MI Koukourakis, A Giatromanolaki, H Sheldon, FM Buffa, G Kouklakis, ... Clinical Cancer Research 15 (22), 7069-7076, 2009 | 60 | 2009 |
| Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms SA Lowndes, HV Sheldon, S Cai, JM Taylor, AL Harris Microvascular research 77 (3), 314-326, 2009 | 50 | 2009 |
| Single cell RNA‐sequencing: A powerful yet still challenging technology to study cellular heterogeneity M Ke, B Elshenawy, H Sheldon, A Arora, FM Buffa Bioessays 44 (11), 2200084, 2022 | 47 | 2022 |
| Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer W Leung, I Roxanis, H Sheldon, FM Buffa, JL Li, AL Harris, A Kong Oncotarget 6 (8), 5678, 2015 | 44 | 2015 |
| Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth CE Oon, E Bridges, H Sheldon, RCA Sainson, A Jubb, H Turley, R Leek, ... Oncotarget 8 (25), 40115, 2017 | 39 | 2017 |
